放疗联合p53腺病毒治疗中晚期宫颈癌近期疗效分析

发布时间：2018-04-29 18:23

  本文选题：宫颈癌 + 调强放疗　； 参考：《安徽医科大学学报》2017年06期

【摘要】：目的评价调强放疗联合重组人p53腺病毒注射液治疗中晚期宫颈癌的近期临床疗效。方法 46例中晚期宫颈癌患者随机分为治疗组(调强放疗联合p53基因治疗)21例和对照组(单纯调强放疗)25例。治疗组给予重组人p53腺病毒注射液瘤内注射每周1次,两组患者放疗剂量和放疗方法相同,治疗结束2个月后,复查评估治疗疗效;并于放疗前后刷取宫颈细胞,行DNA倍体定量分析,比较两组患者宫颈细胞DNA指数≥2.5的细胞个数。结果治疗组完全缓解(CR)13例(61.9%),部分缓解(PR)6例(28.6%),有效率90.5%;对照组CR 7例(28%),PR 9例(36%),有效率64.0%;治疗组有效率明显高于对照组(P0.05)。DNA倍体定量分析放疗后治疗组与对照组差异有统计学意义(χ~2=4.544,P=0.033)。结论影像学及DNA倍体定量分析结论一致,提示重组人p53腺病毒联合调强放疗治疗中晚期宫颈癌近期疗效优于单独放疗组。
[Abstract]:Objective to evaluate the short-term efficacy of IMRT combined with recombinant human p53 adenovirus injection in the treatment of advanced cervical cancer. Methods Forty-six patients with advanced cervical cancer were randomly divided into two groups: treatment group (n = 21) and control group (n = 25). The treatment group was treated with recombinant human p53 adenovirus injection once a week. The dose of radiotherapy was the same as that of radiotherapy in both groups. After 2 months of treatment, the therapeutic effect was evaluated, and cervical cells were brushed before and after radiotherapy. Quantitative analysis of DNA ploidy was performed to compare the number of cervical cell DNA index 鈮，

本文编号：1821059